Treatment of Henoch-Schönlein Purpura in a 6-Year-Old
For most 6-year-old children with Henoch-Schönlein purpura (HSP), supportive care alone is appropriate, as the disease spontaneously resolves in 94% of cases; however, corticosteroids should be used for significant joint pain, severe abdominal symptoms, or renal involvement. 1
Initial Assessment and Risk Stratification
The first critical step is determining disease severity, which dictates treatment intensity:
- Mild disease: Isolated purpura with minimal joint symptoms
- Moderate disease: Significant arthritis/arthralgia or moderate abdominal pain
- Severe disease: Severe abdominal pain, gastrointestinal bleeding, or nephrotic-range proteinuria
All children require urinalysis to detect renal involvement (hematuria, proteinuria), as 30-50% develop kidney disease and this determines long-term prognosis 1, 2.
Treatment Algorithm by Severity
Mild HSP (Purpura ± Minimal Symptoms)
Supportive care is sufficient for children with only rash and minimal symptoms:
- Rest and hydration
- NSAIDs for minor joint discomfort
- No corticosteroids needed
The evidence shows HSP is self-limiting in the vast majority, and corticosteroids do not prevent renal involvement 3. Avoid unnecessary steroid exposure in mild cases.
Moderate HSP (Significant Joint or Abdominal Pain)
Oral prednisone 1-2 mg/kg/day for 2 weeks effectively treats joint and abdominal symptoms 1. A meta-analysis demonstrated that corticosteroids reduce the mean time to resolution of abdominal pain 1.
For your 6-year-old patient with moderate disease, methylprednisolone pulse therapy shows superior efficacy compared to hydrocortisone sodium succinate, particularly in reducing the duration of proteinuria if renal involvement develops 4.
Severe HSP (Severe GI Symptoms or Renal Involvement)
For severe abdominal manifestations or nephrotic-range proteinuria, use methylprednisolone pulse therapy combined with immunosuppression 4, 5:
- Methylprednisolone pulse therapy (typically 10-30 mg/kg/day IV for 3 days)
- Followed by oral prednisone taper
- For severe renal involvement (crescentic nephritis, nephrotic syndrome): add oral cyclophosphamide 2 mg/kg/day for 12 weeks 5
The combination of high-dose corticosteroids plus cyclophosphamide significantly reduces proteinuria in children with HSP nephritis, with protein-to-creatinine ratios decreasing from 6.3 to 0.8 (p=0.002) 5.
Renal Disease Management
Monitor for renal involvement with serial urinalysis for at least 6 months, as kidney disease may develop after initial presentation 2, 1:
- If isolated microscopic hematuria or mild proteinuria develops: continue observation
- If nephritic or nephrotic features appear: consult pediatric nephrology immediately
- Consider renal biopsy for persistent nephrotic-range proteinuria or declining renal function
While corticosteroids do not prevent renal involvement 3, there is moderate evidence they may reduce persistent renal disease when used early 1. For established HSP nephritis with significant histopathologic changes, aggressive immunosuppression is warranted 5.
Critical Pitfalls to Avoid
Do not delay diagnosis in children presenting with severe abdominal pain before rash appears - purpura may not manifest until 2-3 weeks after GI symptoms 6. Consider HSP in the differential for unexplained abdominal pain in this age group.
Do not use corticosteroids prophylactically to prevent renal disease - there is moderate evidence they are ineffective for this purpose 3.
Do not miss bacterial infections - if HSP is triggered by infection, glucocorticoid therapy alone without treating the underlying infection may not relieve symptoms 6.
Monitor for hypertension during corticosteroid treatment - 10 of 12 patients in one series developed hypertension during therapy, though most resolved 5.